Race Oncology Ltd (ASX:RAC)'s Phil Lynch speaks to Proactive after the healthcare stock closed its heavily oversubscribed share purchase plan, raising just under $30 million from more than 2,300 shareholders at $3 per share. He says the volume of subscriptions reflects the potential of Race's lead drug candidate, Zantrene — a compound that's being explored as a new therapy to combat melanoma and clear cell renal cell carcinoma.
Race Oncology brings in $29.7 million war chest to "get to the clinic"
